Business Standard

Eris Lifesciences Q3 PAT up 12% to Rs 90 cr, revenue rises 7%

The company launched four new products in the first nine months of FY22, more on the anvil

Eris Lifesciences
Premium

Eris Lifesciences

Vinay Umarji Ahmedabad
At Rs 100.8 crore, leading Indian branded formulations manufacturing company Eris Lifesciences Ltd. has posted an 11.8 per cent growth in its profit after tax (PAT) for the third quarter ended December 31, 2021 of FY22.

The company had registered a PAT of Rs 90.2 crore for the said period in the previous FY21. The company's revenue, on the other hand, grew by seven per cent to stand at Rs 332.2 crore for Q3 of FY22 as against Rs 310.4 crore in Q3 of FY21. Eris Lifesciences saw its PAT margin improve by 130 basis points to 30.3 per cent on

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 28 2022 | 6:49 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com